The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits
Brain · 2023
DOI: 10.1093/brain/awac473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2023. Verfasst von Rebekah Koppenol und 14 weiteren Autor:innen. Beteiligte Einrichtung: ABC-RI, Algarve Biomedical Center Research Institute, 8005-139 Faro, Portugal. Hauptthemen laut MEDLINE: Spinocerebellar Ataxias, Machado-Joseph Disease. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Portuguese Science and Technology Foundation, French Muscular Dystrophy Association.
Abstract (Originalsprache)
Polyglutamine diseases are a group of neurodegenerative disorders caused by an abnormal expansion of CAG repeat tracts in the codifying regions of nine, otherwise unrelated, genes. While the protein products of these genes are suggested to play diverse cellular roles, the pathogenic mutant proteins bearing an expanded polyglutamine sequence share a tendency to self-assemble, aggregate and engage in abnormal molecular interactions. Understanding the shared paths that link polyglutamine protein expansion to the nervous system dysfunction and the degeneration that takes place in these disorders is instrumental to the identification of targets for therapeutic intervention. Among polyglutamine diseases, spinocerebellar ataxias (SCAs) share many common aspects, including the fact that they involve dysfunction of the cerebellum, resulting in ataxia. Our work aimed at exploring a putative new therapeutic target for the two forms of SCA with higher worldwide prevalence, SCA type 2 (SCA2) and type 3 (SCA3), which are caused by expanded forms of ataxin-2 (ATXN2) and ataxin-3 (ATXN3), respectively. The pathophysiology of polyglutamine diseases has been described to involve an inability to properly respond to cell stress. We evaluated the ability of GTPase-activating protein-binding protein 1 (G3BP1), an RNA-binding protein involved in RNA metabolism regulation and stress responses, to counteract SCA2 and SCA3 pathology, using both in vitro and in vivo disease models. Our results indicate that G3BP1 overexpression in cell models leads to a reduction of ATXN2 and ATXN3 aggregation, associated with a decrease in protein expression. This protective effect of G3BP1 against polyglutamine protein aggregation was reinforced by the fact that silencing G3bp1 in the mouse brain increases human expanded ATXN2 and ATXN3 aggregation. Moreover, a decrease of G3BP1 levels was detected in cells derived from patients with SCA2 and SCA3, suggesting that G3BP1 function is compromised in the context of these diseases. In lentiviral mouse models of SCA2 and SCA3, G3BP1 overexpression not only decreased protein aggregation but also contributed to the preservation of neuronal cells. Finally, in an SCA3 transgenic mouse model with a severe ataxic phenotype, G3BP1 lentiviral delivery to the cerebellum led to amelioration of several motor behavioural deficits. Overall, our results indicate that a decrease in G3BP1 levels may be a contributing factor to SCA2 and SCA3 pathophysiology, and that administration of this protein through viral vector-mediated delivery may constitute a putative approach to therapy for these diseases, and possibly other polyglutamine disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ABC-RI, Algarve Biomedical Center Research Institute, 8005-139 Faro, Portugal.
- PhD Program in Biomedial Sciences, Faculdade de Medicina e Ciências Biomédicas, Universidade do Algarve, 8005-139 Faro, Portugal.
- Faculdade de Medicina e Ciências Biomédicas, Universidade do Algarve, 8005-139 Faro, Portugal.
- Center for Neuroscience and Cell Biology (CNC), University of Coimbra, 3004-504 Coimbra, Portugal.
- Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.
- Champalimaud Research Program, Champalimaud Center for the Unknown, 1400-038 Lisbon, Portugal.
ORCID-Profile: Liliana Mendonça, Luís Pereira de Almeida, Clévio Nóbrega
Förderung
- Portuguese Science and Technology Foundation
- French Muscular Dystrophy Association
Zitieren
APA
Koppenol, R., Conceição, A., Afonso, I. T., Afonso-Reis, R., Costa, R. G., Tomé, S., Teixeira, D., da Silva, J. P., Côdesso, J. M., Brito, D. V. C., Mendonça, L., Marcelo, A., Pereira de Almeida, L., Matos, C. A., & Nóbrega, C. (2023). The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits. Brain. https://doi.org/10.1093/brain/awac473
Vancouver
Koppenol R, Conceição A, Afonso IT, Afonso-Reis R, Costa RG, Tomé S, et al. The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits. Brain. 2023. doi:10.1093/brain/awac473
BibTeX
@article{Koppenol2023,
author = {Koppenol, Rebekah and Conceição, André and Afonso, Inês T and Afonso-Reis, Ricardo and Costa, Rafael G and Tomé, Sandra and Teixeira, Diogo and da Silva, Joana Pinto and Côdesso, José Miguel and Brito, David V C and Mendonça, Liliana and Marcelo, Adriana and Pereira de Almeida, Luís and Matos, Carlos A and Nóbrega, Clévio},
title = {The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits},
journal = {Brain},
year = {2023},
doi = {10.1093/brain/awac473}
}
EUVIMED